Literature DB >> 2925263

Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases.

D Conte1, C Mandelli, M Cesana, R Ferrini, M Marconi, A Bianchi.   

Abstract

Thirteen men and one woman (mean age 48.8 yr +/- 6.9, range 36-63) with idiopathic hemochromatosis were treated by erythrocytapheresis. Iron depletion followed 9.60 months treatment (median 24), with 21-203 erythrocytaphereses (mean 93 +/- 61) and total iron removal of 4.2-40.6 g (mean 19 +/- 11.9). Trasferrin saturation decreased from 90 +/- 8.7% to 17 +/- 10.6% and serum ferritin from 3164 micrograms/L +/- 1488 to 60.5 micrograms/L +/- 77.5, and liver iron content normalized in all cases. Initial serum ferritin in the patients who were iron-depleted at 18 months (50%, cumulative percentage) was significantly lower than in those still iron loaded at that time (2280 micrograms/L +/- 940 vs 4049 micrograms/L +/- 1444, p less than 0.02). Clinical improvement was noted in all cases with about a 30% decrease in insulin requirement in most diabetics. Thus erythrocytapheresis appears to be effective and safe in obtaining iron depletion in idiopathic hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925263

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  3 in total

1.  Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Authors:  Tatjana Sundic; Tor Hervig; Signe Hannisdal; Jörg Assmus; Rune J Ulvik; Richard W Olaussen; Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

Review 2.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.